Logo

PCRX

Pacira BioSciences, Inc.

PCRX

Pacira BioSciences, Inc. • NASDAQ
$23.57 ▼ -1.01% (-0.24)
Market Cap $1.07 B
52w High $27.64
52w Low $16.41
Dividend Yield 0%
P/E 50.15
Volume 248.31K
Outstanding Shares 45.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $179.516M ▼ $138.876M ▲ $5.432M ▲ 3.026% ▲ $0.12 ▲ $34.368M ▲
Q2-2025 $181.099M ▲ $131.734M ▼ $-4.847M ▼ -2.676% ▼ $-0.11 ▼ $29.241M ▼
Q1-2025 $168.923M ▼ $132.627M ▲ $4.812M ▼ 2.849% ▼ $0.1 ▼ $33.609M ▼
Q4-2024 $187.253M ▲ $122.663M ▼ $16.041M ▲ 8.566% ▲ $0.35 ▲ $50.603M ▲
Q3-2024 $168.573M $269.236M $-143.466M -85.106% $-3.11 $-114.754M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $246.334M ▼ $1.298B ▼ $570.363M ▼ $727.214M ▼
Q2-2025 $445.864M ▼ $1.537B ▼ $779.495M ▼ $757.767M ▼
Q1-2025 $493.626M ▲ $1.587B ▲ $788.128M ▲ $798.541M ▲
Q4-2024 $484.615M ▲ $1.554B ▲ $775.168M ▲ $778.348M ▲
Q3-2024 $453.81M $1.522B $772.108M $749.583M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $5.432M ▲ $60.834M ▲ $43.614M ▼ $-257.476M ▼ $-152.895M ▼ $56.964M ▲
Q2-2025 $-4.847M ▼ $12.012M ▼ $62.163M ▲ $-57.505M ▼ $16.874M ▲ $9.315M ▼
Q1-2025 $4.812M ▼ $35.459M ▲ $-25.629M ▼ $-2.994M ▼ $6.836M ▼ $26.911M ▼
Q4-2024 $16.041M ▲ $33.132M ▼ $-368K ▲ $-1.955M ▲ $30.809M ▲ $31.014M ▼
Q3-2024 $-143.466M $53.92M $-52.163M $-2.845M $-1.088M $49.828M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Bupivacaine Liposome Injectable Suspension
Bupivacaine Liposome Injectable Suspension
 $0 ▲$0 ▲$0 ▲$0 ▲
EXPAREL
EXPAREL
 $150.00M ▲$140.00M ▼$140.00M ▲$140.00M ▲
Product
Product
 $190.00M ▲$170.00M ▼$180.00M ▲$180.00M ▲
ZILRETTA
ZILRETTA
 $30.00M ▲$20.00M ▼$30.00M ▲$30.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has climbed steadily over the last five years, showing that Pacira is selling more of its products and expanding its commercial footprint. Profitability, however, has been uneven. The company moved from healthy profits earlier in the period to modest profits and then to a loss in the most recent year. Gross margins remain strong, which means the core products are still attractive economically, but higher expenses — likely from R&D, commercialization, and acquisitions — have pushed operating income and net income into the red. Overall, the business is growing, but recent earnings pressure signals a period of investment and cost intensity rather than clean profit growth.

Balance Sheet

Balance Sheet Pacira’s balance sheet looks reasonably solid but not pristine. Total assets have drifted slightly down from their peak, suggesting some consolidation after prior expansion. Cash has recently improved from low levels, giving the company more near‑term flexibility, although it is still well below the high cash position it once held. Debt rose significantly a few years ago and has since been reduced, but remains a meaningful part of the capital structure. Equity has grown over time, indicating that cumulative value has been built despite the recent loss. In short, the company has a moderate leverage profile with enough resources to support ongoing operations, but limited room for large missteps.

Cash Flow

Cash Flow Cash generation is a clear relative strength. Operating cash flow has been consistently positive and has trended upward over the past five years, even in the year when the company reported an accounting loss. Free cash flow has followed the same pattern, supported by modest capital spending needs. This indicates that the core business is capable of funding itself and contributing to debt service and selective investment. The contrast between positive cash flow and weaker reported earnings suggests that non‑cash items and investment spending are weighing on the income statement more than on actual cash generation.

Competitive Edge

Competitive Edge Pacira occupies a focused and differentiated niche in non‑opioid pain management, anchored by its DepoFoam delivery technology and flagship product EXPAREL. It benefits from proprietary technology, patent protection, and an established commercial presence in surgical settings. The company’s portfolio — including EXPAREL, ZILRETTA, and the iovera° device — offers multiple, non‑opioid ways to manage pain, which aligns well with healthcare and regulatory trends away from opioids. Competition exists, including other extended‑release pain products, but Pacira’s specialization, relationships with hospitals and surgeons, and legislative tailwinds like the NOPAIN Act give it a defensible position with room for further penetration if it executes well.

Innovation and R&D

Innovation and R&D Innovation is central to Pacira’s strategy. Its DepoFoam platform underpins its lead product and showcases the company’s expertise in extended‑release drug delivery. Beyond that, Pacira is moving into gene therapy for osteoarthritis of the knee with PCRX‑201, which has shown encouraging early data and has received a favorable regulatory designation, signaling potential to address a significant unmet need. The acquisition of GQ Bio adds a broader gene therapy platform, and partnerships, such as with Johnson & Johnson MedTech, expand commercial reach. The company’s long‑term growth plan relies on expanding indications for existing products, advancing a small but focused pipeline, and leveraging its technology platforms into new non‑opioid and genetic therapies.

Summary

Pacira is a growing, innovation‑driven pain‑management company with strong product economics and a distinct non‑opioid focus, but with profit volatility as it invests for the future. Revenue and cash flow trends are positive, showing real business traction, while recent accounting losses highlight the cost of R&D, commercialization, and pipeline building. The balance sheet supports continued operation and measured investment, though debt levels and the shift to losses introduce some financial risk that bears watching. Competitively, Pacira benefits from proprietary technology, established brands in a growing therapeutic area, and supportive policy dynamics. Its future outlook hinges on successfully broadening use of its current products and delivering on its gene therapy and pipeline ambitions without overstretching its financial resources.

NEWS

November 26, 2025 · 4:01 PM UTC

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

Read more

November 11, 2025 · 8:00 AM UTC

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Read more

November 10, 2025 · 8:09 PM UTC

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

Read more

November 6, 2025 · 4:01 PM UTC

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

Read more

November 5, 2025 · 8:00 AM UTC

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Read more